Tiny study probes bone microenvironment in metastatic kidney cancer
NCT ID NCT07187869
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early study will look at how two drugs, cabozantinib and nivolumab, change the bone immune environment in 16 people with kidney cancer that has spread to bone. The main goal is to check safety and see how the bone environment responds. It is a proof-of-concept study, meaning it is too small and early to know if this approach will work.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cabozantinib and nivolumab
What this could lead to
If successful, this could help identify better treatment options for kidney cancer that has spread to bone, potentially reducing bone complications.
What could go wrong
This is a very early, small proof-of-concept study with only 16 participants. The main goal is safety, not effectiveness, so results may not lead to new treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••